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Antibiotic prophylaxis may 
not be necessary in patients 
with asymptomatic bacteriuria 
undergoing intradetrusor 
onabotulinumtoxinA injections for 
neurogenic detrusor overactivity
Lorenz Leitner1,2,*, Ulla Sammer1,*, Matthias Walter1, Stephanie C. Knüpfer1, 
Marc P. Schneider1,3, Burkhardt Seifert4, Jure Tornic1, Ulrich Mehnert1 & Thomas M. Kessler1
Many of the patients undergoing intradetrusor onabotulinumtoxinA injections for refractory 
neurogenic detrusor overactivity (NDO) present with chronic bacteriuria. In these patients, antibiotic 
prophylaxis has been widely recommended since bacteriuria might impair treatment efficacy and cause 
urinary tract infections (UTI) but the evidence is limited. The aim of this study was to evaluate if an 
antibiotic prophylaxis is needed in patients with asymptomatic bacteriuria undergoing intradetrusor 
onabotulinumtoxinA injections. Between 06/2012 and 12/2014, a consecutive series of 154 patients 
undergoing a total of 273 treatment cycles were prospectively evaluated. Before treatment urine 
samples were collected, patients with no clinical signs for UTI underwent onabotulinumtoxinA 
injections, no antibiotic prophylaxis was given. Asymptomatic bacteriuria was found in 73% (200/273 
treatments). Following treatment, UTI occurred in 5% (9/200) and 7% (5/73) of patients with and 
without bacteriuria, respectively. Intradetrusor onabotulinumtoxinA injections were clinically 
and urodynamically successful in 70% (192/273). There was no association between bacteriuria 
and treatment-related adverse events (odds ratio 0.64, 95% CI 0.23–1.81, p = 0.4) nor between 
bacteriuria and therapy failure (odds ratio 0.78, 95% CI 0.43–1.43, p = 0.4). Thus, we conclude that 
antibiotic prophylaxis needs to be critically reconsidered in patients undergoing intradetrusor 
onabotulinumtoxinA injections, especially taking into account the alarming antibiotic resistance 
worldwide.
A wide range of neurological disorders may cause neuro-urological symptoms1. According to the Guidelines on 
Neuro-Urology (http://uroweb.org/guideline/neuro-urology/) of the European Association of Urology (EAU), 
lower urinary tract function is impaired in up to 95% of patients with spinal cord injury (SCI)2, up to 96% of 
patients with spina bifida3 and in almost all patients suffering from multiple sclerosis for more than 10 years4. 
Asymptomatic bacteriuria is common in these patients (23–89% if preforming intermittent self-catheterisation 
and up to 100% if reliant on an indwelling catheter), mainly triggered by some type of catheterisation as a result 
of neurogenic lower urinary tract dysfunction5. In patients with neurogenic detrusor overactivity (NDO)1, major 
concerns are high intravesical pressures, which may lead to end stage renal failure, urinary incontinence rele-
vantly impairing quality of life and recurrent urinary tract infections (UTI) with an incidence of 29–36%6.
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Intradetrusor onabotulinumtoxinA injections are generally accepted as a highly effective, minimally invasive 
and well-tolerated therapy for patients suffering from refractory NDO1,7,8. However, there is no consensus on 
the ideal technique of injection, dosage and optimal time intervals until repeated injections. Moreover, the exact 
mechanism of action and long-term effects remain to be elucidated9,10.
As bacteriuria might impair efficacy and cause UTI, antibiotic prophylaxis is a widely-used practice in patients 
undergoing intradetrusor onabotulinumtoxinA injections. Nevertheless, the evidence is very limited and there 
is a lack of specific recommendations in the guidelines of the EAU11,12 and the Infectious Diseases Society of 
America Guidelines (IDSA)5,13.
Therefore, the aim of the present study was to evaluate if antibiotic prophylaxis is needed in patients with 
asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for refractory NDO.
Patients and Methods
Patients. From June 2012 to December 2014, a consecutive series of 154 patients, undergoing a total of 273 
intradetrusor onabotulinumtoxinA injections for NDO were prospectively evaluated at the Spinal Cord Injury 
Center, Balgrist University Hospital, Zürich, Switzerland. Study exclusion criteria were current UTI (defined by 
the presence of ≥ 103 colony forming units/mL (CFU) in urine culture and at least one of the following symptoms/
signs not explained by any other cause: fever >  38 °C, intensification of pain in the bladder/lower back, intensifi-
cation of spasticity, intensification of lower urinary tract symptoms) and age < 18 years. The study including all 
experimental protocols were approved by the local ethics committee (Kantonale Ethikkommission Zürich) and 
is registered with ClinicalTrials.gov (study registration number: NCT01293110). Informed consent was obtained 
from all subjects. Methods were carried out in accordance with the relevant guidelines. All definitions and units 
are according to the standards recommended by the International Continence Society14.
Investigations and treatment. All subjects underwent neuro-urological assessment1 and urodynamic 
investigation (UDI) according to good urodynamic practices following the recommendations of the International 
Continence Society15,16. If applicable for intradetrusor onabotulinumtoxinA injections, patients were enrolled 
into the study. Before treatment, urine samples were collected by sterile catheterisation for urine culture. In 
accordance with previously published guidelines, asymptomatic bacteriuria was defined by the presence of ≥ 102 
CFU5,11 in urine specimens of patients without symptoms/signs (as described above) referable to UTI5. Patients 
with no symptoms/signs for UTI underwent intradetrusor onabotulinumtoxinA injections without antibiotic 
prophylaxis. Patients with UTI were excluded and adequately treated according to the antibiotic sensitivity pat-
tern. 6 weeks after treatment, neuro-urological assessment and UDI were repeated.
Intradetrusor onabotulinumtoxinA injections were routinely performed in local anaesthesia in an outpatient 
setting as described previously17. In brief, lidocaine gel (Instillagel® 2 × 10 mL, Farco-Pharma GmbH, Germany) 
was instilled into the urethra and exposed for 10 minutes. Urethro-cystoscopy was performed in a lithotomy or 
supine position using a rigid or flexible cystoscope in women and men, respectively. Patients received 20 injec-
tions of 1 mL each (10 units onabotulinumtoxinA (Botox® ) per mL) into the detrusor at 20 different sites (i.e. 
200 units onabotulinumtoxinA in total) sparing the trigone.
Safety and efficacy assessments. All adverse events, as defined by the International Conference on 
Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines (E6)18 and International Organization for 
Standardization (ISO, 14155)19, within 6 weeks following the injections, were recorded. Efficacy was assessed by 
clinical and urodynamic parameters.
Outcome measures. Outcome measures were the occurrence of treatment-related adverse events, i.e. 
UTI, gross haematuria and bladder pain upon follow-up UDI 6 weeks after intradetrusor onabotulinumtoxinA 
injections. Furthermore, improvement of clinical (i.e. urinary frequency and incontinence episodes) and urody-
namic parameters (i.e. maximum cystometric capacity (MCC), maximum detrusor pressure during storage phase 
(pdetmax), compliance, presence of detrusor overactivity (DO) and bladder volume at first DO) were evaluated. 
Successful treatment was defined as appropriate clinical (defined as urinary frequency ≤ 8/24 hours and reduction 
of incontinence episodes ≥ 75%) and urodynamic (defined as maximum detrusor pressure during storage phase 
< 40 cmH2O and bladder compliance ≥ 20 mL/cmH2O) effect.
Statistical analyses. Data distribution was assessed by Q-Q plots. Approximately normally distributed data 
were presented as mean ± standard deviation (SD), skewed data as median and interquartile range. Outcomes on 
safety and efficacy between patients with and without bacteriuria at injection time were compared using logistic 
regression analysis. To address clustering of injections within patients, logistic regression analysis was performed 
with safety/efficacy as a dependent variable, asymptomatic bacteriuria as independent variable and robust stand-
ard error (with patients as clusters). For clinically equivalence tests, the confidence interval (CI) inclusion rule 
was used and according to the current literature20,21 a delta interval of ± 23%, i.e. dry rate between 41% and 88%, 
at a CI of 90%, was defined.
Univariate analyses were performed to identify influencing factors associated with urodynamic outcome after treat-
ment, initially with patients as clusters. As clustering did not have any impact on outcome parameters, this was ignored 
for further analyses. Comparing related/unrelated samples, the paired/unpaired t test was used for approximately 
normally distributed data and the Wilcoxon signed rank test/Mann-Whitney U test for skewed data, respectively. For 
comparison of unrelated and related binary data, the chi-square test and McNemar test was used, respectively.
Statistical analyses were performed using Stata 13.1 (StataCorp, College Station, TX, USA) and IBM SPSS Statistics 
for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA) with p < 0.05 considered statistically significant.
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Results
Patients’ characteristics. Patients’ characteristics are shown in Table 1. The mean age at enrolment was 
54 ± 18 and 51 ± 18 years for female (38%, 59/154) and male (62%, 95/154) patients, respectively. A total of 273 
treatments with intradetrusor onabotulinumtoxinA injections were performed.
Bacterial patterns. Asymptomatic bacteriuria was found in 73% (200/273 treatments). The distribution of 
bacterial strains is shown in Fig. 1. In 52% (104/200) of treatments with asymptomatic bacteriuria, a single bac-
terial strain could be isolated, a mixed bacterial pattern of 2, 3 and 4 different bacterial strains was found in 30% 
(60/200), 12% (24/200) and 6% (12/200) of treatments, respectively.
Safety and efficacy. Treatment-related adverse events are presented in Table 2. UTI occurred in 7% (5/73) 
of cases with a sterile urine culture and in 5% (9/200) with asymptomatic bacteriuria (odds ratio 0.64, 95% CI 0.23 
to 1.81, p = 0.4). One patient was hospitalized because of febrile UTI not showing bacteriuria before treatment.
Number of patients 154
Gender
Female 59 (38%)
Male 95 (62%)
Cause of NLUTD
Spinal cord injury 92 (60%)
Tetraplegic 29 (19%)
Paraplegic 63 (41%)
Multiple sclerosis 20 (13%)
Spina bifida 9 (6%)
Spinal stenosis 9 (6%)
Parkinson’s disease 6 (4%)
Others 18 (12%)
Type of bladder emptying
Spontaneous 19 (12%)
Intermittent self-catheterisation 76 (49%)
Indwelling catheter 59 (38%)
Locomotion
Ambulatory 49 (32%)
Wheelchair user 105 (68%)
Table 1.  Patients’ characteristics. NLUTD = neurogenic lower urinary tract dysfunction.
Figure 1. Distribution of bacterial strains. Asymptomatic bacteriuria was found in 73% (200/273 treatments). 
A total of 344 microorganisms and 28 different species could be isolated, including 27 different bacterial 
strains as well as one fungal strain (Candida albicans). Other bacterial species included (listed according to 
frequency): Enterobacteriaceae cloacae, Pseudomonas aeruginosa, Staphylococcus agalactiae, Proteus vulgaris, 
Streptococcus milleri, Serratia marcescens, Streptococcus mitis, Corynebacterium spp., Klebsiella oxytoca, 
Candida albicans, Streptococcus viridans, Providencia stuartii, Citrobacter freundii, Enterobacter aerogenes, 
Aerococcus schaalii, Morganella morganii, Stenotrophomonas maltophilia and Staphylococcus lugdunensis.
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Intradetrusor onabotulinumtoxinA injections were clinically and urodynamically successful in 70% (192/273). 
No association between asymptomatic bacteriuria and therapy failure (odds ratio 0.78, 95% CI 0.43 to 1.43, 
p = 0.4) was detected. The CI inclusion rule revealed a mean difference of 4.9% (90% CI -14% to 6%) in success 
rate, for patient with (success rate 69%) and without bacteriuria (success rate 73.9%); the CI was placed within 
the prior defined delta interval. The onabotulinumtoxinA effect lasted for a mean of 10 months and was not sig-
nificantly (p = 0.56) different between patients with (12 ± 15 months) and without (10 ± 12 months) bacteriuria.
Clinical and urodynamic parameters. Number of different bacterial strains, bacterial load, or method of 
bladder emptying, i.e. spontaneous, intermittent catheterisation or indwelling catheter, did not have any signifi-
cant impact (all p ≥ 0.1) on clinical and/or urodynamic parameters.
Baseline clinical and urodynamic parameters did not differ significantly (Table 3) between patients with and with-
out bacteriuria. A significant treatment effect regarding urinary frequency, incontinence episodes, MCC, pdetmax, 
compliance, DO, and bladder volume at first DO was found in the successfully treated patients (all p < 0.001), again 
no significant difference between patients with and without bacteriuria could be shown (all p > 0.05).
Discussion
Main findings. Investigating a consecutive series of 154 patients with refractory NDO undergoing 273 
intradetrusor onabotulinumtoxinA injections without antibiotic prophylaxis, safety and efficacy of the therapy 
could be ensured, even if asymptomatic bacteriuria was present. Within 6 weeks after treatment, UTI occurred in 
5% (9/200) of the patients with asymptomatic bacteriuria pre-treatment and in 7% (5/73) of those with a sterile 
urine culture. The efficacy rate of 70%, i.e. appropriate clinical and urodynamic effect, was without any association 
between asymptomatic bacteriuria and therapy failure. In addition, there was sustained onabotulinumtoxinA 
effect duration of a mean of 10 months showing no significant differences between patients with and without 
bacteriuria before treatment.
Findings in context of existing evidence. Suprapontine or spinal lesions affect the storage phase and 
result in reduced bladder capacity and NDO, expressed as involuntary contractions of the detrusor1,12. These 
patients often complain about urinary urgency, frequency and incontinence and may suffer from renal failure in 
the long-term if not appropriately treated1,12.
Asymptomatic 
bacteriuria (n = 200)
No bacteriuria 
(n = 73)
No adverse event 188 68
Gross haematuria 1 0
Urinary tract infection 9 5
Bladder pain 1 0
Autonomic dysreflexia 1 0
Table 2.  Treatment-related adverse events (per treatment not per patient).
Success
Pre treatment Pre treatment
p
Post treatment Post treatment
p
Asymptomatic 
bacteriuria (n = 138)
No bacteriuria 
(n = 54)
Asymptomatic 
bacteriuria (n = 138)
No bacteriuria 
(n = 54)
Urinary frequency/24 h 7 ± 4 7 ± 3 0.84 5 ± 1 5 ± 2 0.22
Incontinence episodes/24 h 2 (0–3) 2 (0–3) 0.81 0 (0–0) 0 (0–0) 0.99
MCC [mL] 385 (250–555) 410 (260–595) 0.67 505 (360–715) 535 (510–685) 0.92
Compliance [mL/cmH2O] 45 (25–76) 50 (29–74) 0.58 55 (35–110) 71 (39–107) 0.35
pdetmax storage [cmH2O] 35 (22–54) 40 (20–48) 0.64 19 (11–33) 15 (8–25) 0.05
First DO [mL] 210 (110–325) 230 (120–350) 0.28 325 (190–445) 350 (225–490) 0.28
DO (138/138) (54/54) 0.99 (98/138) (32/54) 0.68
Failure
Asymptomatic 
bacteriuria (n = 62)
No Bacteriuria 
(n = 19)
Asymptomatic 
bacteriuria (n = 62)
No Bacteriuria 
(n = 19)
Urinary frequency/24 h 7 ± 3 7 ± 3 0.57 6 ± 2 6 ± 2 0.67
Incontinence episodes/24 h 1 (1–3) 2 (1–4) 0.27 1 (0–1) 1 (0–2) 0.3
MCC [mL] 330 (195–515) 410 (225–530) 0.24 340 (90–525) 345 (200–450) 0.96
Compliance [mL/cmH2O] 32 (19–73) 40 (27–100) 0.15 33 (20–60) 49 (32–100) 0.06
pdetmax storage [cmH2O] 34 (23–65) 22 (14–48) 0.06 38 (18–58) 34 (21–52) 0.86
First DO [mL] 140 (90–310) 205 (140–370) 0.15 140 (85–270) 190 (105–300) 0.39
DO (62/62) (19/19) 0.99 (57/62) (18/19) 0.12
Table 3.  Clinical and urodynamic data. MCC = maximum cystometric capacity; pdetmax storage = maximum 
detrusor pressure during storage phase; DO = detrusor overactivity; treatment = intradetrusor 
onabotulinumtoxinA injections.
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As to date, efficacy and safety of intradetrusor onabotulinumtoxinA injections has been reported in > 50 
studies including some high-level evidence studies7,8,21–25. This minimally invasive intervention has become a 
well-established second-line treatment for patients with refractory NDO to be considered before more invasive 
therapies such as bladder augmentation, urinary diversion or sacral anterior root stimulation with dorsal rhizot-
omy1,12. After regulatory approval of intradetrusor onabotulinumtoxinA injections by the US Food and Drug 
Administration and the European Union in August 2011 based on the results of two phase 3 studies in patients 
with multiple sclerosis and SCI suffering from NDO incontinence7,8, this treatment is expected to increase world-
wide, especially as efficacy of repeated injections seems given20,26,27. Regarding antibiotic prophylaxis during this 
kind of treatment in patients with NDO, evidence-based specific recommendations do not exist at present time. 
Nevertheless, it is widely used by physicians in daily clinical practice. According to EAU Guidelines on Urological 
Infections11, peri-interventional antibiotic prophylaxis is not generally recommended during cystoscopy and 
fulguration of small bladder tumours, but during TUR-P and procedures breaching of the bladder mucosa and 
therefore considered to be clean-contaminated28,29, always taking additionally into account specific risk factors 
such as indwelling catheters and bacterial burden11. Otherwise neuro-urological patients presenting with asymp-
tomatic bacteriuria should not be treated antimicrobially12 in order to avoid significantly more resistant bacterial 
strains without improvement of outcome. In most previously published studies evaluating safety and efficacy 
of intradetrusor onabotulinumtoxinA injections in patients suffering from NDO, information about the use of 
antibiotic prophylaxis is lacking. Schurch et al. demonstrated significant improvement of clinical and urody-
namic parameters after intradetrusor onabotulinumtoxinA (200 or 300 units) injections compared to placebo in 
patients with NDO caused by multiple sclerosis or SCI. Injections were performed under antibiotic prophylaxis, 
administered for an appropriate period of time - but further details were not given30. Regarding safety, one of 
the main adverse events reported in literature is the development of UTI. However, the variability between the 
studies is wide, after both, treatment and placebo application. Cruz et al.7 reported a prevalence of UTI in about 
22% in the placebo group, 28% in the group treated with 200 units and 38% in the group treated with 300 units 
onabotulinumtoxinA, respectively. Herschorn et al.21 showed a UTI rate of 55% in the patients receiving placebo 
and 57% in patients treated with 200 units onabotulinumtoxinA. In the study by Ginsberg et al.16, UTI occurred 
in 34% after placebo and in approximately 50% after treatment. Schurch et al.30 reported a frequency of UTI 
of about 14% (placebo group) and 32% (200 units onabotulinumtoxinA group), performing injections under 
administration of prophylactic antibiotics whereas kind of medication used and duration of applications were not 
described. However, it should be mentioned that a differentiation between asymptomatic bacteriuria and UTI (or 
often wrongly defined as asymptomatic and symptomatic UTI) was not made in any of these studies. Mouttalib 
et al.31 argued in favour of an antibiotic prophylaxis in patients with refractory NDO undergoing intradetrusor 
onabotulinumtoxinA injections, since they found a UTI incidence rate of about 7% during the first week after 
treatment. In contrast, Game et al.32 described a significant reduction of UTI episodes after injections of 300 units 
onabotulinumtoxinA into the detrusor in 30 patients suffering from NDO emptying the bladder by clean inter-
mittent self-catheterisation, probably as a result of improved bladder function due to appropriate NDO treatment, 
especially considering that a direct antimicrobial effect of onabotulinumtoxinA has not yet been shown33. In our 
present study not using antibiotic prophylaxis, UTI occurred in 7% (5/73) of patients with a sterile urine culture 
and in 5% (9/200) who presented with asymptomatic bacteriuria before intradetrusor onabotulinumtoxinA injec-
tions. Therefore, asymptomatic bacteriuria might not have a negative impact on safety of intradetrusor onabotu-
linumtoxinA injections. In addition, asymptomatic bacteriuria seems not to impair efficacy of this treatment, as 
we were able to demonstrate improvement in clinical and all urodynamic parameters.
Implication for practice. Patients with NDO require an extensive and specific workup before embarking on an 
individualized therapy taking into account the patients’ medical and physical condition as well as their expectations1. 
Based on the data of the present study, antibiotic prophylaxis in patients with asymptomatic bacteriuria undergoing 
intradetrusor onabotulinumtoxinA injections for refractory NDO seems not to be needed and should be critically 
scrutinized in order to avoid the risk of selecting antimicrobial resistance. While awaiting the results of well-designed 
risk-stratification studies, we do not recommend the general use of antibiotic prophylaxis for intradetrusor onabotu-
linumtoxinA injections but it might be considered in selected cases, for instance in immune-compromized patients.
Implication for research. Given the heterogeneous nature and management of NDO, it would be of great inter-
est to know which subgroup of patients is at highest risk to develop UTIs after onabotulinumtoxinA treatment and 
therefore will benefit from an antibiotic prophylaxis. Thus, prospective large-scale multicentre studies are highly war-
ranted to investigate this still unanswered question and to further improve the management of patients with NDO.
Study limitations. Although we evaluated a well-defined patient population with NDO, there are limitations 
that should be addressed. Most of our patients suffered from SCI, i.e. patients with other neurological disorders 
were under-represented. Our unit is part of a highly specialized university SCI centre so that a negative selection 
bias, i.e. inclusion of more severe cases, cannot to be completely ruled out. In addition, our study was not rand-
omized, i.e. we did not compare the outcome of patients with versus without antibiotic prophylaxis. Nevertheless, 
the present study was prospective and representative of daily clinical practice.
Conclusions
Asymptomatic bacteriuria in patients undergoing intradetrusor onabotulinumtoxinA injections for NDO did not 
affect safety and efficacy outcomes. Thus, antibiotic prophylaxis seems not to be justified and needs to be critically 
reconsidered, especially taking into account the alarming antibiotic resistance worldwide.
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